VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
-16.95%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.4B
AUM Growth
+$1.4B
(-17%)
Cap. Flow
-$95.2M
Cap. Flow
% of AUM
-6.8%
Top 10 Holdings %
Top 10 Hldgs %
51.45%
Holding
86
New
13
Increased
27
Reduced
13
Closed
23
Top Buys
| 1 |
Arcellx
ACLX
|
$125M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$50.3M |
| 3 |
Scholar Rock
SRRK
|
$41.8M |
| 4 |
Vera Therapeutics
VERA
|
$34.2M |
| 5 |
Nuvalent
NUVL
|
$33.7M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$120M |
| 2 |
Merck
MRK
|
$79.6M |
| 3 |
Ascendis Pharma
ASND
|
$57.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$56.5M |
| 5 |
Soleno Therapeutics
SLNO
|
$47.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Arcellx
ACLX
$3.85B
| $157M | 11.19% | 2,387,720 +1,912,720 | +403% | +$125M |
|
2
Cytokinetics
CYTK
$4.23B
| $104M | 7.44% | 2,590,531 +240,531 | +10% | +$9.67M |
|
3
Insmed
INSM
$28.8B
| $82M | 5.86% | 1,075,000 +175,000 | +19% | +$13.4M |
|
|
4
Nuvalent
NUVL
$5.52B
| $76.2M | 5.44% | 1,075,000 +475,000 | +79% | +$33.7M |
|
|
5
Vera Therapeutics
VERA
$1.38B
| $60.1M | 4.29% | 2,500,000 +1,425,000 | +133% | +$34.2M |
|
6
KalVista Pharmaceuticals
KALV
$678M
| $54.8M | 3.92% | 4,751,292 -18,708 | -0.4% | -$216K |
|
7
uniQure
QURE
$896M
| $50.8M | 3.63% | 4,792,572 +1,767,572 | +58% | +$18.7M |
|
|
8
Crinetics Pharmaceuticals
CRNX
$2.92B
| $50.3M | 3.59% | +1,500,000 | New | +$50.3M |
|
9
Xenon Pharmaceuticals
XENE
$2.98B
| $43.6M | 3.11% | 1,300,000 +490,000 | +60% | +$16.4M |
|
|
10
Scholar Rock
SRRK
$3.14B
| $41.8M | 2.98% | +1,300,000 | New | +$41.8M |
|
|
BCAX
11
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $36.1M | 2.58% | 2,768,975 +2,058,975 | +290% | +$26.8M |
|
12
Geron
GERN
$893M
| $35M | 2.5% | 22,005,340 +11,005,340 | +100% | +$17.5M |
|
13
Amicus Therapeutics
FOLD
$2.34B
| $34.9M | 2.49% | 4,275,000 +925,000 | +28% | +$7.55M |
|
14
Immatics
IMTX
$619M
| $32.4M | 2.32% | 7,192,700 +917,700 | +15% | +$4.14M |
|
15
Structure Therapeutics
GPCR
$1.11B
| $31M | 2.21% | 1,788,990 +63,990 | +4% | +$1.11M |
|
16
Dianthus Therapeutics
DNTH
$759M
| $30.8M | 2.2% | 1,700,069 +625,069 | +58% | +$11.3M |
|
17
Savara
SVRA
$567M
| $30.5M | 2.18% | 11,000,000 +225,000 | +2% | +$623K |
|
18
Tyra Biosciences
TYRA
$675M
| $26.8M | 1.91% | 2,879,829 +1,889,829 | +191% | +$17.6M |
|
19
Danaher
DHR
$147B
| $25.6M | 1.83% | +125,000 | New | +$25.6M |
|
20
UroGen Pharma
URGN
$900M
| $23.8M | 1.7% | 2,152,957 +522,957 | +32% | +$5.78M |
|
|
21
Ascendis Pharma
ASND
$11.8B
| $23.4M | 1.67% | 150,142 -369,858 | -71% | -$57.6M |
|
22
Astria Therapeutics
ATXS
$349M
| $22.3M | 1.59% | 4,180,000 | – | – |
|
23
Day One Biopharmaceuticals
DAWN
$769M
| $20.6M | 1.47% | 2,598,127 +1,158,127 | +80% | +$9.18M |
|
24
Dyne Therapeutics
DYN
$1.92B
| $18.8M | 1.34% | +1,800,000 | New | +$18.8M |
|
25
Ultragenyx Pharmaceutical
RARE
$2.89B
| $18.1M | 1.29% | 500,000 -1,000,000 | -67% | -$36.2M |
|